<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05114850</url>
  </required_header>
  <id_info>
    <org_study_id>CTS-TRIC-003</org_study_id>
    <nct_id>NCT05114850</nct_id>
  </id_info>
  <brief_title>Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve®</brief_title>
  <official_title>TRICUS REGISTRY - Retrospective Prospective Multicentric Clinical Follow up of Patients With Severe Tricuspid Regurgitation After Being Treated With the TricValve® Transcatheter Bicaval Valves System.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>P+F Products + Features GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>P+F Products + Features GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective prospective Multicentric clinical follow up of patients with severe tricuspid&#xD;
      regurgitation after being treated with the TricValve® Transcatheter Bicaval Valves System.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study shall enrol subjects who were treated with the TricValve® Transcatheter Bicaval&#xD;
      Valves System® in the Inferior Vena Cava and Superior vena cava. On compliance with the&#xD;
      inclusion / exclusion criteria the subject will be enrolled for the observational study.&#xD;
&#xD;
      The study duration for the individual subject will be up to 5 year follow up. The follow-up&#xD;
      should be made through pre-established periodic clinical consultations at discharge, 1 month,&#xD;
      6 months, 1 year follow up to 5 years after the procedure. In the consultations, routine&#xD;
      exams such as hemogram, renal function, electrocardiogram and echocardiography in order to&#xD;
      ascertain the bioprosthesis functioning and its hemodynamic profile are documented as per&#xD;
      clinical routine practise.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Number of patients with readmission for HF</measure>
    <time_frame>up to 12 months</time_frame>
    <description>First unplanned readmission for Heart Failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>up to 30 days, up to 6 months, up to 5 years</time_frame>
    <description>Number of patients in terms of all cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with major adverse events</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Percentage of participants with major adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with severe adverse events</measure>
    <time_frame>up to 30 days, up to 6 months, up to 5 years</time_frame>
    <description>Number of participants with severe adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with readmission for HF</measure>
    <time_frame>up to 5 years</time_frame>
    <description>First unplanned readmission for Heart Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA functional class</measure>
    <time_frame>up to 30 days, up to 6 months, up to 5 years</time_frame>
    <description>Change of New York Heart Association (NYHA) functional class from III or IV to a lower one</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BNP/NTproBNP and diuretic dosage</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Change in BNP/NTproBNP and diuretic dosage before intervention after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the right atrium size</measure>
    <time_frame>up to 30 days, up to 6 months, up to 5 years</time_frame>
    <description>Change of the Right Atrium Size assessed by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the free valve movement</measure>
    <time_frame>up to 30 days, up to 6 months, up to 5 years</time_frame>
    <description>Change of the free valve movement assessed by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve Device Regurgitation</measure>
    <time_frame>up to 30 days, up to 6 months, up to 5 years</time_frame>
    <description>Number of patients with valve device regurgitation assessed by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of alive patients</measure>
    <time_frame>up to 30 days, up to 6 months, up to 5 years</time_frame>
    <description>Number of alive patients free from reintervention related to TricValve System</description>
  </secondary_outcome>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <condition>Tricuspid Valve Insufficiency</condition>
  <condition>Tricuspid Insufficiency</condition>
  <condition>Heart Failure</condition>
  <condition>Heart Diseases</condition>
  <condition>Heart Valve Diseases</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study shall enrol subjects who were treated with the TricValve® Transcatheter Bicaval&#xD;
        Valves System® in the Inferior Vena Cava and Superior vena cava. On compliance with the&#xD;
        inclusion / exclusion criteria the subject will be enrolled for the observational study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Successful treatment with TricValve Transcatheter Bicaval Valves System&#xD;
&#xD;
          -  Patient/patient's authorized legal guardian gives his consent to participate in the&#xD;
             study and signed the corresponding inform consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no exclusion criterion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ignacio J Amat Santos, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario de Valladolid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sandra Scheidl, MSc</last_name>
    <phone>+436601148208</phone>
    <email>sscheidl@pfcardiovascular.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Benjamin Reutterer, Dr</last_name>
    <phone>+4369917237200</phone>
    <email>breutterer@pfcardiovascular.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian Hengstenberg, UnivProf Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Omar Jawad Altisent, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia de Córdoba</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Manuel Pan Alvarez, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Luis Nombela Franco, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Raul Moreno, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Ángel Sánchez Recalde, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Ignacio Cruz, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Ignacio J Amat Santos, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Alvaro Cunqueiro</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrés Iniguez Romo, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 29, 2021</study_first_submitted>
  <study_first_submitted_qc>October 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

